Optogenetics: implications for Alzheimer's disease research and therapy
Parsa Mirzayi1,2, Parnian Shobeiri1,2,3,4, Amirali Kalantari1,2
1School of Medicine, Tehran University of Medical Sciences (TUMS), Children's Medical Center Hospital, Dr. Qarib St., Keshavarz Blvd, 14194, Tehran, Iran.
Molecular Brain
|February 24, 2022
Summary
Optogenetics has revolutionized Alzheimer's disease (AD) research by revealing insights into neural circuits and cognitive functions. This technology offers potential therapeutic strategies to reverse memory impairments in AD patients.
Area of Science:
- Neuroscience
- Neurodegenerative Diseases
- Optogenetics
Background:
- Alzheimer's disease (AD) significantly impacts brain activity, particularly synaptic plasticity and neuronal circuits.
- The precise mechanisms underlying these impairments in AD remain largely unknown.
Purpose of the Study:
- To review the advancements in understanding Alzheimer's disease (AD) through optogenetics.
- To explore the potential of optogenetic interventions as future therapeutic strategies for AD.
Main Methods:
- Optogenetics has been instrumental in studying neural circuits affected by Alzheimer's disease.
- Review of optogenetically driven methods and their impact on AD research.
Main Results:
- Optogenetics has significantly enhanced our understanding of the neural networks involved in cognitive functions affected by AD.
- Optogenetic approaches have demonstrated the ability to reduce and reverse neural circuit and memory impairments in AD models.
Conclusions:
- Optogenetics has driven a revolution in neuroscience, particularly in Alzheimer's disease research.
- Optogenetic interventions show promise for future clinical translation and therapeutic applications in Alzheimer's disease.
Related Concept Videos
01:22Alzheimer's Disease: Treatment
279
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
279
01:26Alzheimer's Disease: Overview
713
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
713